Base de dados : MEDLINE
Pesquisa : D10.251.860 [Categoria DeCS]
Referências encontradas : 131 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 14 ir para página                         

  1 / 131 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173136
[Au] Autor:Bai T; Chen Y; Jiang W; Yan F; Fan Y
[Ad] Endereço:1 Department of Applied Mechanics, Sichuan University, Chengdu, China.
[Ti] Título:Studies on Foam Decay Trend and Influence of Temperature Jump on Foam Stability in Sclerotherapy.
[So] Source:Vasc Endovascular Surg;52(2):98-106, 2018 Feb.
[Is] ISSN:1938-9116
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: This study investigated the influence of temperature jump and liquid-gas ratio on foam stability to derive the foam-decay law. METHODS: The experimental group conditions were as follows: mutation temperatures (10°C, 16°C, 20°C, 23°C, 25°C, and 27°C to >37°C) and liquid-gas ratios (1:1, 1:2, 1:3, and 1:4). The control group conditions were as follows: temperatures (10°C, 16°C, 20°C, 23°C, 25°C and 27°C) and liquid-gas ratios (1:1, 1:2, 1:3, and 1:4). A homemade device manufactured using the Tessari DSS method was used to prepare the foam. The decay process was videotape recorded. In the drainage rate curve, the temperature rose, and the liquid-gas ratio varied from 1:1 to 1:4, causing faster decay. RESULTS: In the entire process, the foam volume decreased with increasing drainage rate. The relationships were almost linear. Comparison of the experimental and control groups shows that the temperature jump results in a drainage time range of 1 to 15 seconds. The half-life ranges from 10 to 30 seconds. The maximum rate is 18.85%. Changes in the preparation temperature yields a drainage time range of 3 to 30 seconds. The half-life varies from 20 to 60 seconds. CONCLUSION: Decreasing the temperature jump range and liquid-gas ratio gradually enhances the foam stability. The foam decay time and drainage rate exhibit an exponential function distribution.
[Mh] Termos MeSH primário: Soluções Esclerosantes/química
Escleroterapia/métodos
Morruato de Sódio/química
Temperatura Ambiente
[Mh] Termos MeSH secundário: Estabilidade de Medicamentos
Meia-Vida
Modelos Lineares
Modelos Químicos
Transição de Fase
Fatores de Tempo
Gravação em Vídeo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Sclerosing Solutions); 8031-09-2 (Sodium Morrhuate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1177/1538574417741786


  2 / 131 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
PubMed Central Texto completo
Texto completo
[PMID]:24635447
[Au] Autor:Rabago D; Patterson JJ; Mundt M; Zgierska A; Fortney L; Grettie J; Kijowski R
[Ad] Endereço:1 Department of Family Medicine, University of Wisconsin School of Medicine and Public Health , Madison WI.
[Ti] Título:Dextrose and morrhuate sodium injections (prolotherapy) for knee osteoarthritis: a prospective open-label trial.
[So] Source:J Altern Complement Med;20(5):383-91, 2014 May.
[Is] ISSN:1557-7708
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: This study determined whether injection with hypertonic dextrose and morrhuate sodium (prolotherapy) using a pragmatic, clinically determined injection schedule for knee osteoarthritis (KOA) results in improved knee pain, function, and stiffness compared to baseline status. DESIGN: This was a prospective three-arm uncontrolled study with 1-year follow-up. SETTING: The setting was outpatient. PARTICIPANTS: The participants were 38 adults who had at least 3 months of symptomatic KOA and who were in the control groups of a prior prolotherapy randomized controlled trial (RCT) (Prior-Control), were ineligible for the RCT (Prior-Ineligible), or were eligible but declined the RCT (Prior-Declined). INTERVENTION: The injection sessions at occurred at 1, 5, and 9 weeks with as-needed treatment at weeks 13 and 17. Extra-articular injections of 15% dextrose and 5% morrhuate sodium were done at peri-articular tendon and ligament insertions. A single intra-articular injection of 6 mL 25% dextrose was performed through an inferomedial approach. OUTCOME MEASURES: The primary outcome measure was the validated Western Ontario McMaster University Osteoarthritis Index (WOMAC). The secondary outcome measure was the Knee Pain Scale and postprocedure opioid medication use and participant satisfaction. RESULTS: The Prior-Declined group reported the most severe baseline WOMAC score (p=0.02). Compared to baseline status, participants in the Prior-Control group reported a score change of 12.4±3.5 points (19.5%, p=0.002). Prior-Decline and Prior-Ineligible groups improved by 19.4±7.0 (42.9%, p=0.05) and 17.8±3.9 (28.4%, p=0.008) points, respectively; 55.6% of Prior-Control, 75% of Prior-Decline, and 50% of Prior-Ineligible participants reported score improvement in excess of the 12-point minimal clinical important difference on the WOMAC measure. Postprocedure opioid medication resulted in rapid diminution of prolotherapy injection pain. Satisfaction was high and there were no adverse events. CONCLUSIONS: Prolotherapy using dextrose and morrhuate sodium injections for participants with mild-to-severe KOA resulted in safe, significant, sustained improvement of WOMAC-based knee pain, function, and stiffness scores compared to baseline status.
[Mh] Termos MeSH primário: Terapias Complementares/métodos
Glucose/administração & dosagem
Osteoartrite do Joelho/tratamento farmacológico
Morruato de Sódio/administração & dosagem
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Injeções Intra-Articulares
Masculino
Meia-Idade
Estudos Prospectivos
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
8031-09-2 (Sodium Morrhuate); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1502
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140319
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1089/acm.2013.0225


  3 / 131 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24477936
[Au] Autor:Giurgius M; Fearing N; Weir A; Micheas L; Ramaswamy A
[Ad] Endereço:Department of Surgery, University of Missouri, Columbia, MO, USA.
[Ti] Título:Long-term follow-up evaluation of endoscopic sclerotherapy for dilated gastrojejunostomy after gastric bypass.
[So] Source:Surg Endosc;28(5):1454-9, 2014 May.
[Is] ISSN:1432-2218
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Endoscopic sclerotherapy using sodium morrhuate has been used to treat patients with weight regain after Roux-en-Y gastric bypass whose presumed etiology is loss of restriction due to gastrojejunostomy dilation. Weight loss and stability have been demonstrated in several studies with short-term follow-up evaluation. METHODS: This retrospective review evaluated all the patients who underwent sclerotherapy for a dilated gastrojejunostomy between 2007 and 2012. RESULTS: The study identified 48 patients with a mean follow-up period of 22 months (range 12-60 months). The mean age of these patients was 47.5 ± 10.5 years, and 92 % were women. The average weight loss from the primary procedure was 132.5 ± 54.82 lb, and the average weight regain from the lowest weight to the maximum weight before sclerotherapy was 46 ± 40.32 lb. The median number of sclerotherapy sessions was two (range 1-4). The pre-procedure mean gastrojejunostomy diameter was 20 ± 3.6 mm, and the mean volume of sodium morrhuate injected per session was 12.8 ± 3.7 ml. The average weight loss from sclerotherapy to the final documented weight was 3.17 ± 19.70 lb, which was not statistically significant. The following variables in the multivariate analysis were not associated with statistically significant weight loss: volume of sodium morrhuate, patient age, gastrojejunostomy diameter, number of sclerotherapy sessions, decrease in gastrojejunostomy diameter between the first and second sessions, and number of follow-up years. Weight stabilization or loss was achieved by 58 % of our cohort, with a mean weight loss of 15.9 ± 14.6 lb in this subgroup. CONCLUSION: The long-term follow-up evaluation of patients undergoing sclerotherapy of the gastrojejunostomy for weight regain after gastric bypass showed only a marginal weight loss, which was not statistically significant in our study population, although more than 50 % of the patients achieved weight loss or stabilization.
[Mh] Termos MeSH primário: Endoscopia Gastrointestinal/métodos
Derivação Gástrica/métodos
Cuidados Pós-Operatórios/métodos
Complicações Pós-Operatórias/terapia
Escleroterapia/métodos
Morruato de Sódio/administração & dosagem
Ganho de Peso
[Mh] Termos MeSH secundário: Dilatação Patológica/terapia
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
Soluções Esclerosantes/administração & dosagem
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Sclerosing Solutions); 8031-09-2 (Sodium Morrhuate)
[Em] Mês de entrada:1411
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140131
[St] Status:MEDLINE
[do] DOI:10.1007/s00464-013-3376-7


  4 / 131 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:23291605
[Au] Autor:Rabago D; Lee KS; Ryan M; Chourasia AO; Sesto ME; Zgierska A; Kijowski R; Grettie J; Wilson J; Miller D
[Ad] Endereço:Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53715, USA.
[Ti] Título:Hypertonic dextrose and morrhuate sodium injections (prolotherapy) for lateral epicondylosis (tennis elbow): results of a single-blind, pilot-level, randomized controlled trial.
[So] Source:Am J Phys Med Rehabil;92(7):587-96, 2013 Jul.
[Is] ISSN:1537-7385
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Chronic lateral epicondylosis is common, debilitating, and often refractory. Prolotherapy (PrT) is an injection therapy for tendinopathy. The efficacy of two PrT solutions for chronic lateral epicondylosis was evaluated. DESIGN: This study is a three-arm randomized controlled trial. Twenty-six adults (32 elbows) with chronic lateral epicondylosis for 3 mos or longer were randomized to ultrasound-guided PrT with dextrose solution, ultrasound-guided PrT with dextrose-morrhuate sodium solution, or watchful waiting ("wait and see"). The primary outcome was the Patient-Rated Tennis Elbow Evaluation (100 points) at 4, 8, and 16 wks (all groups) and at 32 wks (PrT groups). The secondary outcomes included pain-free grip strength and magnetic resonance imaging severity score. RESULTS: The participants receiving PrT with dextrose and PrT with dextrose-morrhuate reported improved Patient-Rated Tennis Elbow Evaluation composite and subscale scores at 4, 8, and/or 16 wks compared with those in the wait-and-see group (P < 0.05). At 16 wks, compared with baseline, the PrT with dextrose and PrT with dextrose-morrhuate groups reported improved composite Patient-Rated Tennis Elbow Evaluation scores by a mean (SE) of 18.7 (9.6; 41.1%) and 17.5 (11.6; 53.5%) points, respectively. The grip strength of the participants receiving PrT with dextrose exceeded that of the PrT with dextrose-morrhuate and the wait and see at 8 and 16 wks (P < 0.05). There were no differences in magnetic resonance imaging scores. Satisfaction was high; there were no adverse events. CONCLUSIONS: PrT resulted in safe, significant improvement of elbow pain and function compared with baseline status and follow-up data and the wait-and-see control group. This pilot study suggests the need for a definitive trial.
[Mh] Termos MeSH primário: Solução Hipertônica de Glucose/uso terapêutico
Qualidade de Vida
Amplitude de Movimento Articular/efeitos dos fármacos
Morruato de Sódio/uso terapêutico
Cotovelo de Tenista/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Doença Crônica
Quimioterapia Combinada
Feminino
Seguimentos
Seres Humanos
Injeções Intra-Articulares
Masculino
Meia-Idade
Medição da Dor
Projetos Piloto
Amplitude de Movimento Articular/fisiologia
Valores de Referência
Medição de Risco
Índice de Gravidade de Doença
Método Simples-Cego
Cotovelo de Tenista/diagnóstico por imagem
Resultado do Tratamento
Ultrassonografia Doppler
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Glucose Solution, Hypertonic); 8031-09-2 (Sodium Morrhuate)
[Em] Mês de entrada:1308
[Cu] Atualização por classe:161215
[Lr] Data última revisão:
161215
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:130108
[St] Status:MEDLINE
[do] DOI:10.1097/PHM.0b013e31827d695f


  5 / 131 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22983137
[Au] Autor:Winkler S; Grässel S; Baier C; Anders S; Lechler P; Grifka J; Schaumburger J
[Ad] Endereço:Department of Orthopaedic Surgery, University of Regensburg, Bad Abbach, Germany. Sebastian.Winkler@klinik.uni-regensburg.de
[Ti] Título:The impact of chemical synovectomy with sodium morrhuate on human chondrocytes and cartilage in vitro.
[So] Source:Rheumatol Int;33(5):1201-6, 2013 May.
[Is] ISSN:1437-160X
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The vessel sclerosing property of sodium morrhuate is useful in treatment of recurrent joint effusions particularly in cases of knee joint effusions. It also can be employed as an addition to surgical synovectomy. Little is known about the effects of this drug on cartilage. This study was designed to investigate the cytotoxic impact of sodium morrhuate on human chondrocytes and cartilage tissue in vitro. Primary chondrocytes from 13 patients were isolated and cultivated in three-dimensional alginate cultures. Furthermore, femoral cartilage explants of 10 patients were cultivated in vitro. Both chondrocytes and cartilage explants were exposed to mixture of sodium morrhuate and mepivacaine in different concentrations simulating chemical synovectomy. After 48 h, cell proliferation, viability, and cytotoxicity were measured. The cartilage specimens were analyzed for apoptosis by immunohistochemistry. Up to a dilution of 1:600, cells were found to be 100 % viable with a proliferation rate of 74 % compared to controls. From 1:400 onwards, a significant increase in LDH release was measured which reached at dilution of 1:200 74 % of high control, whereas histological examination showed no proof of apoptosis or necrosis in cartilage tissue. The results of this in vitro study demonstrate that the cytotoxic effects of sodium morrhuate on human chondrocytes, which lack their original extracellular matrix, manifest between dilutions of 1:500 and 1:400 and increase with higher concentrations of the drug. This effect was not found for cartilage explants, though.
[Mh] Termos MeSH primário: Cartilagem Articular/efeitos dos fármacos
Condrócitos/efeitos dos fármacos
Soluções Esclerosantes/farmacologia
Escleroterapia/métodos
Morruato de Sódio/farmacologia
[Mh] Termos MeSH secundário: Idoso
Apoptose/efeitos dos fármacos
Cartilagem Articular/patologia
Proliferação Celular/efeitos dos fármacos
Sobrevivência Celular/efeitos dos fármacos
Células Cultivadas
Condrócitos/patologia
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Imuno-Histoquímica
Masculino
Mepivacaína/farmacologia
Meia-Idade
Necrose
Cultura Primária de Células
Soluções Esclerosantes/toxicidade
Escleroterapia/efeitos adversos
Morruato de Sódio/toxicidade
Fatores de Tempo
Técnicas de Cultura de Tecidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Sclerosing Solutions); 8031-09-2 (Sodium Morrhuate); B6E06QE59J (Mepivacaine)
[Em] Mês de entrada:1311
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120918
[St] Status:MEDLINE
[do] DOI:10.1007/s00296-012-2518-x


  6 / 131 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22987598
[Au] Autor:Tu JB; Dong Q; Hu XY; Jiang F; Ma RZ; He LY; Yang ZQ
[Ad] Endereço:Department of Oral and Maxillofacial Surgery, Stomatological Hospital, Xi'an Jiaotong University, Xi'an 710004, People's Republic of China. tujunbo@mail.xjtu.edu.cn
[Ti] Título:Proteomic analysis of mitochondria from infantile hemangioma endothelial cells treated with sodium morrhuate and its liposomal formulation.
[So] Source:J Biochem Mol Toxicol;26(9):374-80, 2012 Sep.
[Is] ISSN:1099-0461
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hemangioma is the most common benign tumor of infancy. The aim of this study is to evaluate the biological effects of sodium morrhuate (SM) and its liposomal formulation on infantile hemangioma endothelial cells (IHECs). Morphological analysis revealed that exposure to liposomal sodium morrhuate (LSM) preferentially caused apoptotic death in IHECs, manifested as shrunken configuration and formation of apoptotic bodies. In contrast, necrotic death was prominent in IHECs treated with an equal concentration of SM. By means of proteomic analysis and confirmation experiments, we revealed that the apoptosis-inducing effects of LSM were associated with an upregulation of a set of genes involved in mitochondrial death pathway, including apoptosis-inducing factor, cytochrome c1, caspase-8, and lamin B1. In conclusion, our data highlight the proapoptotic activity of LSM in IHECs through the mitochondrial apoptotic pathway and may provide a promising avenue to treat hemangiomas of infancy.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Células Endoteliais/efeitos dos fármacos
Hemangioma/metabolismo
Mitocôndrias/metabolismo
Proteínas Mitocondriais/metabolismo
Proteoma/metabolismo
Morruato de Sódio/farmacologia
[Mh] Termos MeSH secundário: Apoptose/efeitos dos fármacos
Fator de Indução de Apoptose/genética
Fator de Indução de Apoptose/metabolismo
Caspase 8/genética
Caspase 8/metabolismo
Forma Celular
Citocromos c1/genética
Citocromos c1/metabolismo
Composição de Medicamentos
Expressão Gênica/efeitos dos fármacos
Hemangioma/tratamento farmacológico
Hemangioma/patologia
Seres Humanos
Lactente
Lamina Tipo B/genética
Lamina Tipo B/metabolismo
Lipossomos
Proteínas Mitocondriais/genética
Proteoma/genética
Proteômica
Células Tumorais Cultivadas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (AIFM1 protein, human); 0 (Antineoplastic Agents); 0 (Apoptosis Inducing Factor); 0 (Lamin Type B); 0 (Liposomes); 0 (Mitochondrial Proteins); 0 (Proteome); 0 (lamin B1); 8031-09-2 (Sodium Morrhuate); 9035-42-1 (Cytochromes c1); EC 3.4.22.- (CASP8 protein, human); EC 3.4.22.- (Caspase 8)
[Em] Mês de entrada:1302
[Cu] Atualização por classe:120918
[Lr] Data última revisão:
120918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120919
[St] Status:MEDLINE
[do] DOI:10.1002/jbt.21436


  7 / 131 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:22817783
[Au] Autor:Abu Dayyeh BK; Jirapinyo P; Weitzner Z; Barker C; Flicker MS; Lautz DB; Thompson CC
[Ad] Endereço:Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02115, USA.
[Ti] Título:Endoscopic sclerotherapy for the treatment of weight regain after Roux-en-Y gastric bypass: outcomes, complications, and predictors of response in 575 procedures.
[So] Source:Gastrointest Endosc;76(2):275-82, 2012 Aug.
[Is] ISSN:1097-6779
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Weight regain after Roux-en-Y gastric bypass (RYGB) is common. Endoscopic sclerotherapy is increasingly used to treat this weight regain. OBJECTIVES: To report safety, outcomes, durability, and predictors of response to sclerotherapy in a large prospective cohort. DESIGN: Retrospective analysis of a prospective cohort study of patients with weight regain after RYGB. PATIENTS: A total of 231 consecutive patients undergoing 575 sclerotherapy procedures between September 2008 and March 2011. INTERVENTIONS: Single or multiple sclerotherapy procedures to inject sodium morrhuate into the rim of the gastrojejunal anastomosis. MAIN OUTCOME MEASUREMENTS: We report weight loss, complications, and predictors of response. We also used Kaplan-Meier survival analysis and log-rank test to compare time to continuation of weight regain after sclerotherapy in patients undergoing a single versus multiple sclerotherapy procedures. RESULTS: At 6 and 12 months from the last sclerotherapy procedure, weight regain stabilized in 92% and 78% of the cohort, respectively. Those who underwent 2 or 3 sclerotherapy sessions had significantly higher rates of weight regain stabilization than those who underwent a single session (90% vs 60% at 12 months; P = .003). The average weight loss at 6 months from the last sclerotherapy session for the entire cohort was 10 lb (standard deviation 16), representing 18% of the weight regained after RYGB. A subset of 73 patients (32% of the cohort) had greater weight loss at 6 months (26 lb, standard deviation 12), representing 61% of the weight regained. Predictors of a favorable outcome included greater weight regain and the number of sclerotherapy procedures. Bleeding was reported in 2.4% of procedures and transient diastolic blood pressure increases in 15%, without adverse health outcomes. No GI perforations were reported. CONCLUSIONS: Endoscopic sclerotherapy appears to be a safe and effective tool for the management of weight regain after RYGB.
[Mh] Termos MeSH primário: Derivação Gástrica
Gastroscopia
Obesidade Mórbida/terapia
Soluções Esclerosantes/uso terapêutico
Escleroterapia/métodos
Morruato de Sódio/uso terapêutico
Ganho de Peso
[Mh] Termos MeSH secundário: Adulto
Relação Dose-Resposta a Droga
Feminino
Seguimentos
Seres Humanos
Estimativa de Kaplan-Meier
Modelos Lineares
Masculino
Meia-Idade
Análise Multivariada
Obesidade Mórbida/cirurgia
Estudos Retrospectivos
Escleroterapia/efeitos adversos
Fatores de Tempo
Falha de Tratamento
Resultado do Tratamento
Perda de Peso
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Sclerosing Solutions); 8031-09-2 (Sodium Morrhuate)
[Em] Mês de entrada:1212
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120724
[St] Status:MEDLINE
[do] DOI:10.1016/j.gie.2012.03.1407


  8 / 131 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22541380
[Au] Autor:Yelland MJ; Bissett L; Rabago D; Patterson J
[Ti] Título:Can double blinding distort results in randomized controlled trials?
[So] Source:PM R;4(4):322-3; author reply 323, 2012 Apr.
[Is] ISSN:1934-1563
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anti-Inflamatórios/administração & dosagem
Glucocorticoides/administração & dosagem
Metilprednisolona/análogos & derivados
Soluções Esclerosantes/administração & dosagem
Morruato de Sódio/administração & dosagem
Cotovelo de Tenista/tratamento farmacológico
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Glucocorticoids); 0 (Sclerosing Solutions); 8031-09-2 (Sodium Morrhuate); X4W7ZR7023 (Methylprednisolone)
[Em] Mês de entrada:1209
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120501
[St] Status:MEDLINE
[do] DOI:10.1016/j.pmrj.2012.02.013


  9 / 131 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:21927902
[Au] Autor:Schaumburger J; Trum S; Anders S; Beckmann J; Winkler S; Springorum HR; Grifka J; Lechler P
[Ad] Endereço:Department of Orthopedic Surgery, University of Regensburg, Asklepios Klinikum Bad Abbach, Kaiser Karl V Allee 3, 93077 Bad Abbach, Regensburg, Germany.
[Ti] Título:Chemical synovectomy with sodium morrhuate in the treatment of symptomatic recurrent knee joint effusion.
[So] Source:Rheumatol Int;32(10):3113-7, 2012 Oct.
[Is] ISSN:1437-160X
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to assess the efficacy and safety of intra-articular sodium morrhuate injections in the treatment of recurrent knee joint effusions. Ninety-eight knees of 92 patients (f = 59, m = 33) with knee arthritis of heterogeneous etiology were treated with chemical synovectomy (CSO). Of those, 39 patients suffered from rheumatoid arthritis (RA). The mean follow-up was 29.8 months. Clinical outcome was evaluated by analyzing subjective patient satisfaction, activity level, pain severity on the basis of the Visual Analogue Pain Scale (VAS), Lysholm and Gillquist score, and the Knee Injury and Osteoarthritis Outcome Score (KOOS). Fifty-seven percent of all patients and 67% of patients diagnosed with RA were satisfied with CSO. No significant effects on patient satisfaction by CSO were noted in patients older than 40 years. Overall, VAS, Lysholm and Gillquist score, and KOOS improved significantly at final review. The intra-articular application of sodium morrhuate is an effective and safe measure in the treatment of recurrent symptomatic knee joint effusions in young patients suffering from recurrent knee joint effusions.
[Mh] Termos MeSH primário: Artrite/tratamento farmacológico
Articulação do Joelho/efeitos dos fármacos
Morruato de Sódio/uso terapêutico
Membrana Sinovial/efeitos dos fármacos
Sinovite/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Artralgia/etiologia
Artralgia/prevenção & controle
Artrite/diagnóstico
Artrite/fisiopatologia
Artrite Reumatoide/tratamento farmacológico
Artrite Reumatoide/patologia
Feminino
Seres Humanos
Injeções Intra-Articulares
Articulação do Joelho/patologia
Articulação do Joelho/fisiopatologia
Masculino
Meia-Idade
Medição da Dor
Satisfação do Paciente
Recuperação de Função Fisiológica
Recidiva
Estudos Retrospectivos
Morruato de Sódio/administração & dosagem
Morruato de Sódio/efeitos adversos
Inquéritos e Questionários
Membrana Sinovial/patologia
Sinovite/diagnóstico
Sinovite/fisiopatologia
Fatores de Tempo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
8031-09-2 (Sodium Morrhuate)
[Em] Mês de entrada:1302
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110920
[St] Status:MEDLINE


  10 / 131 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21871414
[Au] Autor:Carayannopoulos A; Borg-Stein J; Sokolof J; Meleger A; Rosenberg D
[Ad] Endereço:Department of Neurosurgery, Lahey Clinic, Burlington, MA, USA.
[Ti] Título:Prolotherapy versus corticosteroid injections for the treatment of lateral epicondylosis: a randomized controlled trial.
[So] Source:PM R;3(8):706-15, 2011 Aug.
[Is] ISSN:1934-1563
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To compare the efficacy of prolotherapy versus corticosteroid injection for the treatment of chronic lateral epicondylosis. DESIGN: A prospective, randomized controlled, double-blinded study. SETTING: Academic, tertiary, outpatient, rehabilitation hospital. PARTICIPANTS: Twenty-four subjects with clinically determined chronic (ie, lasting 3 months or longer) lateral epicondylosis were recruited. All subjects noted pain intensity levels significant enough to prevent the participation in activities, such as playing racquet sports or lifting heavy objects. METHODS: Subjects were assigned to receive either prolotherapy or corticosteroid injection for treatment of chronic lateral epicondylosis. Each subject underwent injection at baseline followed by a second injection 1 month later. OUTCOME MEASUREMENTS: Visual analog scale (VAS) self-rating of pain, quadruple visual analog scale (QVAS), and the Disabilities of the Arm, Shoulder, and Hand questionnaire (DASH) were measured at baseline and at 1, 3, and 6 months' follow-up. RESULTS: Within each group, the analysis demonstrated statistically significant improvements in both VAS and DASH within the prolotherapy group with significant changes noted from baseline to 3 months (VAS: Δ2.38; 95% confidence interval [95% CI] 1.04-3.71, P = .004 and DASH: Δ19.89; 95% CI 5.73-34.04, P = .01), and baseline to 6 months (VAS: Δ2.63; 95% CI 0.61-4.62, P = .017 and DASH: Δ21.76; 9% CI 7.43-36.09, P = .009) after initial treatment, as well as in the QVAS from baseline to 3 months. The steroid group demonstrated a clinically and statistically significant change for DASH only at both 3-month (Δ13.33; 95% CI 0.68-25.99, P = .04) and 6-month (Δ15.56; 95% CI 1.30-29.81, P = .04) follow-up. Comparison of the subjects completing the study revealed no significant differences between the prolotherapy and the corticosteroid group for change in VAS, QVAS, or DASH, although the study lacked sufficient power to draw conclusions from this finding. Eighty-three percent of the subjects were satisfied with their overall improvement during the course of the study, without significant differences revealed between groups. Aside from injection-associated pain, no adverse reactions were reported. Seventeen subjects completed study protocol. CONCLUSIONS: Both prolotherapy and corticosteroid therapy were generally well tolerated and appeared to provide benefit of long duration. Small sample size precludes determining whether one therapy is superior to the other. Larger, controlled trials appear feasible and warranted on the basis of these findings.
[Mh] Termos MeSH primário: Anti-Inflamatórios/administração & dosagem
Glucocorticoides/administração & dosagem
Metilprednisolona/análogos & derivados
Soluções Esclerosantes/administração & dosagem
Morruato de Sódio/administração & dosagem
Cotovelo de Tenista/tratamento farmacológico
[Mh] Termos MeSH secundário: Doença Crônica
Método Duplo-Cego
Força da Mão/fisiologia
Seres Humanos
Injeções Intra-Articulares
Metilprednisolona/administração & dosagem
Dinamômetro de Força Muscular
Medição da Dor
Estudos Prospectivos
Cotovelo de Tenista/fisiopatologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Glucocorticoids); 0 (Sclerosing Solutions); 43502P7F0P (methylprednisolone acetate); 8031-09-2 (Sodium Morrhuate); X4W7ZR7023 (Methylprednisolone)
[Em] Mês de entrada:1201
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110830
[St] Status:MEDLINE
[do] DOI:10.1016/j.pmrj.2011.05.011



página 1 de 14 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde